Innovative Intranasal Nanocarriers of Butyrylcholinesterase and Kinase Inhibitors for Alzheimer’s Disease: Immunohistochemistry, Biomarkers, Histopathology, and Antioxidant Perspective
The RV-KI-NLC formulation showed superior neuroprotective effects in scopolamine-induced AD-like symptoms, with significant improvements in neuronal integrity, reduced neuroinflammation, enhanced cognitive function, and strong antioxidant activity, highlighting its potential as a promising therapeutic strategy for AD.
Authors
- Pirthi Pal Singh (ORCID: https://orcid.org/0000-0001-5367-8147)
- Suhel Pervez
- Zufika Qamar (ORCID: https://orcid.org/0000-0001-5239-2497)
- Ashif Iqubal
- Sameer Khan
- Sanjula Baboota
- Javed Ali
- Neha Bhardwaj
Institutions
- Jamia Hamdard (IN)
- Shree Guru Gobind Singh Tricentenary University (IN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_102657
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00